Application of ossein-hydroxyapatite complex for osteoporosis and fracture treatment (literature review)
Keywords:ossein-hydroxyapatite complex, osteoporosis, fractures
Based on scientific information and the results of our studies suggest the influence of ossein-hydroхyapatite complex in treating patients with osteoporosis, fractures, and pseudarthrosis after arthroplasty. The drug contains growth factors (insulin-like growth factor-1 and 2, transforming growth factor-beta), which stimulates the proliferation and differentiation preosteogenic forming cells and regenerate specific tissue structures. Osteocalcin and collagen type I as components of ossein regulate osteoblast activity and bone remodeling and is the basis for the formation of matrix and for its mineralization. Mineral component of the drug, hydroxyapatite, contains calcium and phosphorus (2:1), and promotes osteoid mineralization, a full-fledged bone regenerate formation, maintaining the stability of bone matrix. As a result of experimental and clinical studies conducted in Ukraine and abroad, effectiveness of ossein-hydroxyapatite complex in patients with primary and secondary osteoporosis is proved. It is proved its positive impact for pain reducing in patients with degenerative diseases of the spine and knee joint arthritis. Established optimization impact of ossein-hydroxyapatite complex at all stages of reparative osteogenesis in various clinical situations of fracture regeneration, as well as in osteosynthesis. It was successfully used in patients with delayed union of long bone fractures. Presented evidence that the use of ossein-hydroxyapatite o complex helps to reduce the incidence of pseudarthrosis. The drug is effective in children with traumatic injuries and violation of long bones. Proven effectiveness of its use in the treatment of patients with osteopenia and osteoporosis after cementless-total hip arthroplasty.
Johnell O, Kanis J. Epidemiology of osteoporotic fractures. Osteoporosis International. 2005;16(2):3–7.
Povoroznyuk VV, Grigorieva NV. Menopause and musculoskeletal system. Kyiv: Express, 2004. 512p.
Ringe JD. Look problems. Osteo Review. 2006;1(1):1.
Castelo-Branco C, Dávila Guardia J. Use of ossein-hydroxyapatite complex in the prevention of bone loss: a review Climacteric. 2015;18(1):29–37. doi: 10.3109/13697137.2014.929107.
Castelo-Branco C. Haya-Palazuelos J, Cancelo-Hidalgo MJ. Menopause and osteoporosis: usefulness of ossein-hydroxyapatite complex. Madrid, Spain: Ed. Medica Panamericana, 2007. pp. 217–25.
Lotinun S, Kiviranta R, Matsubara T, Alzate JA, Neff L, Lüth A, Koskivirta I, Kleuser B, Vacher J, Vuorio E, Horne WC, Baron R. Osteoclast-specific cathepsin K deletion stimulates S1P-dependent bone formation. J Clin. Invest. 2013;123:666–81. doi: 10.1172/JCI64840
Lorenc RS, Hoszowski K, Tłustochowicz W. Efficacy and safety of ossein-hydroxyapatite complex 800 mg tablets and 3200 mg sachets versus calcium carbonate in osteoporotic postmenopausal women. Osteoporosis Int. 1998;8(3):102.
Lugli R. Bruneti G, Salvioli G. Effect of ossein-hydroxyapatite compound on back pain in the elderly. Results of a placebo controlled trial. Clin Trials J. 1990;27:141–148.
Chavassieux P, Pastoureau P, Boivin G, Delmas PD, Chapuy MC, Meunier PJ. Effects of ossein-hydroxyapatite compound on ewe bone remodeling: biochemical and histomorphometric study. J Clin Rheumatol. 1991;10:269–273.
Yang X, Tare RS, Partridge KA, Roach HI, Clarke NM, Howdle SM, Shakesheff KM, Oreffo RO. Induction of human osteoprogenitor chemotaxis, proliferation, differentiation, and bone formation by osteoblast stimulating factor-1/pleiotrophin: osteoconductive biomimetic scaffolds for tissue engineering. J Bone Miner Res. 2003;18:47–57.
Srimongkol T, Bunyaratavej N. Clinical study of efficacy of hydroxyapatite. J Med Assoc Thai. 2005;88(5):24–6.
Ciria-Recasens M, Blanch-Rubió J, Coll-Batet M, Del Pilar Lisbona-Pérez M, Díez-Perez A, Carbonell-Abelló J, Manasanch J, Pérez-Edo L. Comparison of the effects of ossein-hydroxyapatite complex and calcium carbonate on bone metabolism in women with senile osteoporosis: a randomized, open-label, parallel-group, controlled, prospective study. Clin Drug Investig. 2011;31(12):817–24. doi: 10.2165/11592930-000000000-00000.
Noor Z. Nanohydroxyapatite application to osteoporosis management. J Osteoporos. 2013;2013:679025. doi: 10.1155/2013/679025.
Castelo-Branco C, Dávila GJ, Alvarez L, Balash J. Comparison of the effects of calcium carbonate and ossein-hydroxyapatite complex on back and knee pain and quality of life in osteopenic perimеnopausal women. Maturitas. 2015;81(1):76–82. doi: 10.1016/j.maturitas.2015.02.265.
Rodionova SS, Colondannes AF, Sokolov VA, Markov SA. The use of Osteogenon in traumatology and orthopedics. Journal of Traumatology and Orthopedics N. N. Priorov. 2001;4:41–46.
Povoroznyuk VV, Orlik TV, Kolomiets EN. Ossein-hydroxylapatite complex (Osteogenon) in the prevention and treatment of osteoporosis and its complications. Orthopedics, Traumatology and Prosthetics. 2004;(1):1–7.
Haya-Palazue J, Castelo-Branco C, Cancelo-Hidalgo MJ, et al. Safety and efficacy of ossein-hydroxyapatite complex for the prevention of osteoporosis during perimenopause. A three year follow-up study. Maturitas. 2015;81(1):170–175.
Fernández-Pareja A, Hernández-Blanco E, Pérez-Maceda JM, Riera Rubio VJ, Palazuelos JH, Dalmau JM. Prevention of osteoporosis. Four-year follow-up of a cohort of postmenopausal women treated with an ossein-hydroxyapatite compound. Clin. Drugs Invest. 2007;27(4):227–32.
Castelo-Branco C, Ciria-Recasens M, Cancelo-Hidalgo MJ, Palacios S, Haya-Palazuelos J, Carbonell-Abelló J, Blanch-Rubió J, Martínez-Zapata MJ, Manasanch J, Pérez-Edo L. Efficacy of ossein-hydroxyapatite complex compared with calcium carbonate to prevent bone loss: a meta-analysis. Menopause. 2009 Sep-Oct;16(5):984–91. doi: 10.1097/gme.0b013e3181a1824e.
Pelayo I, Haya J, De la Cruz JJ, Seco C, Bugella JI, Diaz JL, Bajo JM, Repolles M. Raloxifene plus ossein-hydroxyapatite compound versus raloxifene plus calcium carbonate to control bone loss in postmenopausal women: a randomized trial. Menopause. 2008;15:1132–338. doi: 10.1097/gme.0b013e318170af33.
Giannoudis PV, Einhorn TA, Marsh D. Fracture healing: the diamond concept. Injury. 2007;38(4):3–6.
Kazakova VS, Novikov OO, Zhilyakova ET. Prospects for the use of growth factors in the reconstruction of bone tissue. Scientific results. Series: Medicine & Pharmacy. 2015. pp. 151–8.
Dedukh NV, Khmyzov SA, Tihonenko AA. New technologies in bone regeneration: the use of growth factors. Orthopaedics, Traumatology and Prosthetics. 2008;(4):129–133.
Tikhonenko AA, Dedukh NV, Bengus LM, Khmyzov SA. Bone regeneration in the background of the local effects of insulin-like growth factor-1 (experimental study). Orthopаedics, Traumatology and Prosthetics. 2014;(1):94–9. doi: http://dx.doi.org/10.15674/0030-59872014163-71.
Korzh NA, Dedukh NV. Reparative bone regeneration: a modern view on the problem. regeneration step (1st message). Orthopаedics, Traumatology and Prosthetics. 2006;(1):77–84.
Calori GM, Giannoudis PV. Enhancement of fracture healing with the diamond concept: the role of the biological chamber. Injury. 2011;42(11):1191–3. doi: 10.1016/j.injury.2011.04.016.
Geris L, Gerisch A, Sloten JV, Weiner R, Oosterwyck HV. Angiogenesis in bone fracture healing: a bioregulatory model. J Theor. Biol. 2008;251(1):137–58.
Goridova LD, Romanenko KK. Nonunion of the humerus (risk factors) // Orthopаediсs, Traumatology and Prosthetic. 2000;(3):72–6.
Dedukh NV, Malyshkina SV, Dursunov AM. The regeneration of the bone defect with the drug administered to animals osteogenon. Orthopаedics, Traumatology and Prosthetics. 2004;(2):40–5.
Campos WG. Effect of the ossein-hydroxyapatite complex on fracture consolidation under protein malnutrition: experimental study using rats. Acta Ortop. Bras. 2001;9(2):21–5.
Zimmermann G, Henle P, Küsswetter M, Moghaddam A, Wentzensen A, Richter W, Weiss S. TGF-beta1 as a marker of delayed fracture healing. Bone. 2005. 36;5:779–85.
Krylov MU, Maslov KA, Korotkov TA, et al. The gene polymorphism of transforming growth factor beta 1 in postmenopausal osteoporosis. Scientific and practical rheumatology. 2009;1:18–23.
Korzh NA, Gerasimenko SI, Klimovitskiy VG, Loskutov OE, Romanenko KK, Gerasimenko A, Kolomiets O. The prevalence of bone fractures and the results of their treatment in the Ukraine (clinic and epidemiological study). Orthopedics, Traumatology and Prosthetics. 2010;(3):5–14. doi: http://dx.doi.org/10.15674/0030-5987201035-14.
Kalashnikov AV. Osteogenon use in the treatment of patients with impaired reparative bone formation after bone fractures. Orthopedics, Traumatology and Prosthetics. 2001;(4):38–42.
Klimovitskiy VG, Sandpiper VY. The frequency of nonunion of fractures in affected different age groups and the influence of osteotrophic therapy. Injury. 2011;13(12). Access mode: http://www.mif-ua.com/archive/article/23297.
Gulnazarova SV, Kuznetsova OA. Optimizing treatment outcomes of patients with pseudarthrosis of long bones of the lower extremities, complicated with osteoporosis. Access mode: http://bone-surgery.ru/view/optimizaciya_ishodov_lecheniya_pacientov_s_lozhnymi_sustavami_dlinnyh_koste.
Izmalkov SN, Lartsev Y. Osteogenon Application in complex treatment of patients with fractures of the bones of the skeleton. Herald of Traumatology and Orthopedics N. N. Priorov. 2001;3:33–35.
Heifetz LM, Marusenko IM, Varga OJ, Vezikova N. Osteogenon in the treatment of fractures of the distal radius in patients with secondary osteoporosis. Therapeutic Archives. 2007;3:52–4.
Korzh NA, Goridova LD, Leontieva FS. Clinical and metabolic aspects of Osteogenon in the treatment of patients with fractures of the long bones. Orthopedics, Traumatology and Prosthetics. 2003;(2):94–9.
Lytvyn JP, Kushnirenko AH. Influence of «Osteogenon» to regenerate bone density in patients with long bone fractures, according to a spiral computed tomography. Orthopedics, Traumatology and Prosthetics. 2005;(4):67–70.
Loskutov AE, Makarov VB, Sinegubov DA, Bredikhin AV. Influence Osteogenon on bone mineral density during arthroplasty in patients with osteopenia and osteoporosis. Оrthopаedics, traumatology and prosthetics. 2005;(2):67–72.
Krys-Pugach AP, Gaiko OG. The results of using «Osteogenon» drug in children with orthopedic pathology. Оrthopаedics, traumatology and prosthetics. 2001;(4):62–4.
Rodionova SS, Torgashin AN. Practical recommendations for the rehabilitation and reconstruction activity after fracture. Access mode: http://centrosteoporoza.ru/wp-content/uploads/2015/04/mp.pdf.
Copyright (c) 2016 Mykola Korzh, Ninel Dedukh
This work is licensed under a Creative Commons Attribution 4.0 International License.
The authors retain the right of authorship of their manuscript and pass the journal the right of the first publication of this article, which automatically become available after 6 months from the date of publication under the terms of Creative Commons Attribution License, which allows others to freely distribute the published manuscript with mandatory linking to authors of the original research and the first publication of this one in this journal.
Authors have the right to enter into a separate supplemental agreement on the additional non-exclusive distribution of manuscript in the form in which it was published by the journal (i.e. to put work in electronic storage of an institution or publish as a part of the book) while maintaining the reference to the first publication of the manuscript in this journal.
The editorial policy of the journal allows authors and encourages manuscript accommodation online (i.e. in storage of an institution or on the personal websites) as before submission of the manuscript to the editorial office, and during its editorial processing because it contributes to productive scientific discussion and positively affects the efficiency and dynamics of the published manuscript citation (see The Effect of Open Access).